The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
NCT ID: NCT06321575
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
159 participants
INTERVENTIONAL
2024-06-20
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis
NCT00712257
Clinical Investigation of the GORE® Drug-Coated PTA Balloon Catheter (GORE® DCB Catheter)
NCT02907203
VEST Venous Graft External Support Pivotal Study
NCT03209609
Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
NCT01330628
Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System in the Treatment of Iliac and Femoropopliteal Lesions Via Transradial Access
NCT05399680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Golazo® Peripheral Atherectomy System
Treatment atherectomy of the peripheral vasculature with the Golazo® Peripheral Atherectomy System.
Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Candidate for atherectomy of the peripheral vasculature in the lower limbs
3. Life expectancy \>1 year in the opinion of the investigator
4. Resting ankle brachial index (ABI) ≤0.90, or ≤0.75 after exercise. Subjects with non-compressible arteries shall have a toe brachial index (TBI) assessment.
5. Target limb Rutherford clinical classification category 3 to 5
6. Suitable candidate for angiography and endovascular intervention in the opinion of the investigator
7. Willing and able to comply with the protocol-specified procedures and assessments
8. Informed consent granted
9. Target lesion(s) defined as stenosis ≥70% by angiographic visual estimation
10. Total treated lesion length ≤20 cm by angiographic visual estimation
11. Target reference vessel diameter (RVD) ≥2.0 mm and ≤4.5 mm by angiographic visual estimation
12. Target limb will have a minimum of one patent (less than 50% stenosis) below the knee (BTK) vessel crossing the ankle, distal to any target lesion, providing perfusion to the foot at baseline
Exclusion Criteria
2. History of an endovascular procedure or open vascular surgery on the target limb within the last 30 days
3. Planned surgical or interventional procedure within 30 days after the index procedure
4. Lesion in the contralateral limb requiring intervention during the index procedure or within next 30 days
5. Critical limb ischemia (CLI) with Rutherford clinical classification category 6
6. Significant acute or chronic kidney disease with a GFR \<30 and/or requiring dialysis
7. Acute myocardial infarction (non-ST-elevation myocardial infarction or ST-segment elevation myocardial infarction) or other uncontrolled comorbidity in the opinion of the investigator
8. Myocardial infarction (MI) or stroke within two months of baseline evaluation
9. Pregnant or lactating
10. Subject is participating in another clinical investigation of a device, drug, or procedure that has not completed the study treatment or that clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)
11. Contraindication to antiplatelet, anticoagulant, or thrombolytic therapy
12. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count \<125,000/microliter, known coagulopathy, or international normalized ratio (INR) \>1.5
13. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately medicated
14. History of heparin-induced thrombocytopenia (HIT)
15. Any thrombolytic therapy within two weeks of enrollment
16. Target lesion(s) within a native vessel graft or synthetic graft
17. Significant stenosis or occlusion of inflow not successfully treated before the index procedure
18. Any evidence or history of intracranial or gastrointestinal bleeding or intracranial aneurysm
19. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)
20. One or more of the following complications of the foot:
1. Osteomyelitis that extends to the metatarsal bones.
2. Gangrene involving the plantar skin of the forefoot, midfoot or heel
3. Deep ulcer or large shallow ulcer (\>3cm) involving the plantar skin of the forefoot, midfoot, or heel
4. Any heel ulcer with/without calcaneal involvement
5. Any wound with calcaneal bone involvement
6. Wounds that are deemed to be neuropathic or non-ischemic in nature
7. Wounds that require flap coverage or complete wound management for large soft tissue defect
21. Congestive heart failure with a NYHA functional classification of III or higher
22. More than 2 lesions to be treated with the investigational device; lesions located within 3 mm may be considered a single tandem lesion
23. Clinical/angiographic complication (other than non-flow limiting dissections) attributed to a currently marketed device prior to introduction of the investigational device
24. In-stent restenosis within the target lesion(s)
25. Potentially unstable or flow-limiting dissection, type C or greater
26. Clinical/angiographic evidence of distal embolization
27. Inability to cross the proximal lesion vessel lumen with a guidewire (not subintimal)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bright Research Partners
INDUSTRY
Yale Cardiovascular Research Group
OTHER
Avantec Vascular
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew Finn, MD
Role: PRINCIPAL_INVESTIGATOR
Cardiovascular Institute of the South
Craig Walker, MD
Role: PRINCIPAL_INVESTIGATOR
Cardiovascular Institute of the South
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HonorHealth Scottsdale Osborn Medical Center
Scottsdale, Arizona, United States
Pulse Cardiovascular Institute
Scottsdale, Arizona, United States
Merced Vascular
Merced, California, United States
Palm Vascular Center
Fort Lauderdale, Florida, United States
First Coast Cardiovascular Institute
Jacksonville, Florida, United States
Radiology and Imaging Specialists of Lakeland
Lakeland, Florida, United States
Amavita Research Services
Miami, Florida, United States
Cardiovascular Consultants of South Georgia
Thomasville, Georgia, United States
Pacific Vascular Institute
‘Aiea, Hawaii, United States
Baton Rouge General Hospital
Baton Rouge, Louisiana, United States
Cardiovascular Institute of the South - Houma
Houma, Louisiana, United States
Cardiovascular Institute of the South - Lafayette
Lafayette, Louisiana, United States
Vascular Breakthroughs
Plymouth, Massachusetts, United States
Advanced Heart and Vascular Institute
Flemington, New Jersey, United States
Spartanburg Regional Medical Center
Spartanburg, South Carolina, United States
Tennessee Center for Clinical Trials
Tullahoma, Tennessee, United States
Hope Vascular & Podiatry
Houston, Texas, United States
Bellin Health
Green Bay, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anita Ramaiah, MD
Role: primary
Lauren Montgomery
Role: backup
Jamie Mooney
Role: primary
Mary Hamilton
Role: backup
Elizabeth Gagne
Role: primary
Maria Myslinski
Role: backup
Alexis Bellafiore
Role: primary
Erin Squindo
Role: backup
Katherine Guilliams
Role: primary
Christen Piaskowski
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AVA-CL-5000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.